Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Merck, Gilead score in effort to develop the first weekly HIV pill
A combination of Merck’s islatravir and Gilead’s lenacapavir has
597 words~3 min read
Related reading
Gilead, Merck’s phase 3 data back first weekly HIV pill
Detailed phase 3 results suggest the two-drug combination of Gilead Sciences’ lenacapavir and Merck & Co.’s islatravir has what…
Merck stages expanded access to monthly HIV PrEP pill ahead of approval
Following in the footsteps of Gilead Sciences, Merck & Co. | Following in the footsteps of Gilead, Merck has signed voluntary…
Gilead christens Bixlenvo with FDA nod for new HIV treatment combo tablet
Some 20 years after helping introduce the first once-daily single tablet HIV regimen, Gilead Sciences has crossed the regulatory…
Drugmakers don’t have ‘duty to innovate’, California court rules, backing…
Years of litigation surrounding Gilead Sciences’ tenofivor-based HIV treatments have come to an end, with the California Supreme…
Gilead's Livdelzi scores in rare liver disease trial, portending use in broader…
A phase 3 study of Gilead’s Livdelzi has met its primary endpoint,
In draft guidance, NICE rebuffs Gilead's twice-a-year PrEP med for national…
In a move that at least one local HIV charity has deemed “profoundly disappointing,” England's health technology assessor NICE is…
